twoXAR operates a proprietary AI-driven discovery platform that identifies promising drug candidates in weeks rather than years and reports in vivo success rates significantly greater than traditional approaches. The company is building a pipeline of novel, proprietary drug candidates through partnerships with biopharmaceutical companies, drug developers, and investors. twoXAR has demonstrated candidate activity across therapeutic areas including liver cancer, rheumatoid arthritis, and type 2 diabetes. Proceeds from the new financing will be used to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates. The team in Palo Alto includes experts in drug discovery, biomedical informatics, computational biology, data science, and software development. twoXAR emphasizes translating computational hits into de‑risked preclinical programs and advancing them to the clinic through industry collaborations. twoXAR is a Palo Alto company advancing a digital approach to drug discovery through its DUMA™ platform. Its patent-pending algorithms evaluate massive public and proprietary datasets to identify and rank high-probability drug–disease matches faster than wet-lab approaches. These matches are used to prioritize existing candidates, perform targeted searches, and identify novel drug candidates for further clinical testing. twoXAR has identified multiple candidates that are currently in preclinical studies in collaboration with patient advocacy groups, academic researchers, and biopharmaceutical organizations. The technology has been tested on more than 20 diseases to date. The company raised $3.4M in seed financing to expand engineering and commercial teams and to advance partnerships focused on metabolic and neurological disease candidates.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2018